Loading...
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
Caracciolo, Daniele Mancuso, Antonia Polerà , Nicoletta Froio, Caterina D'Aquino, Giuseppe Riillo, Caterina Tagliaferri, Pierosandro Tassone, Pierfrancesco
Caracciolo, Daniele
Mancuso, Antonia
Polerà , Nicoletta
Froio, Caterina
D'Aquino, Giuseppe
Riillo, Caterina
Tagliaferri, Pierosandro
Tassone, Pierfrancesco
Citations
Altmetric:
Genre
Journal article
Date
2023-01-09
Advisor
Committee member
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1186/s40164-022-00368-w
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult haematologic disease still associated with an unsatisfactory cure rate. Unlike B-ALL, the availability of novel therapeutic options to definitively improve the life expectancy for relapsed/resistant patients is poor. Indeed, the shared expression of surface targets among normal and neoplastic T-cells still limits the efficacy and may induce fratricide effects, hampering the use of innovative immunotherapeutic strategies. However, novel monoclonal antibodies, bispecific T-cell engagers (BTCEs), and chimeric antigen receptors (CAR) T-cells recently showed encouraging results and some of them are in an advanced stage of pre-clinical development or are currently under investigation in clinical trials. Here, we review this exciting scenario focusing on most relevant advances, challenges, and perspectives of the emerging landscape of immunotherapy of T-cell malignancies.
Description
Citation
Citation to related work
BMC
Has part
Experimental Hematology and Oncology, Vol. 12, Iss. 1
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu